HSPA5 has the effect of up-regulating the GPX4, which results in protecting glioma cells from ferroptosis, indicating the activation of ATF4 strengthens the drug resistance of glioma (Chen Y. et al., 2019). Here, GPX4 is linked to central nervous system cancer.